A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Smoke-free policies in public places like bars and restaurants were linked to lower systolic blood pressures (SBPs) among participants from the longitudinal CARDIA study, according to new research published in the Journal of the American Heart Association.

When consumers think of wearable personal health devices, they likely picture smartwatches or other wrist-worn gadgets. But as Forbes pointed out in a Nov. 26 article, new headphone-type wearables—dubbed “hearables”—have already grown into a $5 billion market and offer unique capabilities.

Almost 1 in 5 patients are rehospitalized within 30 days of undergoing catheter ablation of MI-associated ventricular tachycardia (VT), according to a study from the Nationwide Readmissions Database. These patients rack up 38.9 percent higher cumulative hospital costs than those who aren’t readmitted, researchers reported in Circulation: Arrhythmia and Electrophysiology.

Ambra Health, makers of the leading cloud-based, medical image management suite, today announced a new collaboration with Google Cloud to advance healthcare research with anonymized medical imaging data.

Monitoring digoxin concentration and platelet activation in atrial fibrillation (AF) patients treated with vitamin K antagonists could be important for reducing those patients’ inherently elevated risk for CVD, according to a study published in the Journal of the American Heart Association Nov. 15.

Half a decade of planning and millions of dollars have culminated in the Alliance for Cardiovascular Diagnostic and Treatment Innovation (ADVANCE), a joint engineering and cardiology center launched by Johns Hopkins University in an attempt to improve the diagnosis and treatment of a range of arrhythmia disorders.

Scientists at the University of Oxford are pitching cardiologists a new model for heart regeneration research: the Mexican tetra fish, a blind, translucent animal with an innate ability to repair its damaged heart tissue.